Universe Pharmaceuticals Business Summary

Universe Pharmaceuticals INC (UPC) operates as a specialized pharmaceutical producer and distributor in China, primarily generating revenue through the manufacturing and sale of proprietary traditional Chinese medicine (TCM) derivatives. The company’s business model is bifurcated into two primary segments: the production of own-brand TCM products—specifically targeting chronic conditions in the elderly and cold/flu treatments—and the distribution of third-party biomedical drugs, medical instruments, and dietary supplements. As of early 2026, the company reported annual revenues of approximately $17.86 million, though it faces significant headwinds including a multi-year revenue decline and persistent Nasdaq delisting risks. UPC competes directly with other China-based micro-cap pharmaceutical players such as China SXT Pharmaceuticals (SXTC), China Pharma Holdings (CPHI), and Akanda Corp (AKAN), occupying a niche but volatile position within the specialized TCM market for aging populations. Founded in 1998 and headquartered in Ji’an, Jiangxi, the company is led by Chairman and CEO Gang Lai, who has spearheaded its strategic direction since inception and recently oversaw the implementation of a dual-class share structure effective February 13, 2026. The core leadership team includes Chief Financial Officer Lin Yang and Chief Operating Officer Baochang Liu, both of whom manage the company’s complex regulatory compliance and distribution networks across 30 Chinese provinces. While the firm is largely retail-owned, notable institutional interest has been recorded from the Sabby Volatility Warrant Master Fund, which maintains a 4.9% passive stake, and UBS Group AG. The board of directors, recently re-elected in late 2025, includes experienced members such as Jiawen Pang, Ding Zheng, and Yongping Yu, who provide oversight as the company attempts to stabilize its balance sheet through registered direct offerings and share consolidations.